Diabetes

Some patients may have difficulty managing the gastrointestinal adverse effects associated with GLP-1 therapies.

Losing even 5% of body weight can improve comorbid conditions and other health complications for individuals with overweight and obesity.

Catch up on important diabetes news from the month of July.

From 2021 to 2022, the prevalence of adults with diabetes who used cannabis increased by 33.7%.

Patients with childhood type 1 diabetes were more likely to develop substance use disorders, mood disorders, anxiety disorders, and behavioral syndromes.

Had Novo Nordisk’s insulin icodec secured FDA approval, it would have been the first and only once-weekly basal insulin option for adults with diabetes.

Previously, data from head-to-head trials of tirzepatide and semaglutide were not available.

When used together, sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were able to lower the risk of major adverse cardiovascular events and kidney disease by 11% and 33%, respectively.

Six abstracts presented at the American Diabetes Association 84th Scientific Sessions explored how different interventions or factors can impact type 2 diabetes (T2D) management.

Individuals who ate diets that aligned closer to DASH and Mediterranean guidelines had lower levels of plasminogen activator inhibitor-1 and homocysteine biomarkers.

Three posters presented at the American Diabetes Association 84th Scientific Sessions examined GLP-1 use and cardiovascular disease risk in several different patient populations.

Three posters presented at the American Diabetes Association 84th Scientific Sessions looked into the current landscape of GLP-1s.

Two posters presented at the American Diabetes Association 84th Scientific Sessions looked into the impact of glucagon-like peptide-1 receptor agonists in type 1 diabetes management.

Test your pharmacy news knowledge with our weekly quiz.

Two posters presented at the American Diabetes Association 84th Scientific Sessions looked at challenges of remote CGM in older populations and after discharge from the hospital.

Two abstracts presented at the American Diabetes Association 84th Scientific Sessions explored how positive user experiences with a CGM can lead to better patient outcomes.

At the American Diabetes Association 84th Scientific Sessions, researchers presented findings from 4 studies that investigated the impact of various new diabetes technologies on managing the condition.

Access to diabetes self-management education and support services are crucial for improving diabetes outcomes.

Check out some of the latest research into diabetes medication options.

The Victoza generic is approved for use in adults and children aged 10 years and older.

Skin complications are common in patients with diabetes, but pharmacists can recommend several easy measures to help.

Two posters presented at ENDO 2024 assessed semaglutide’s impact on taste sensitivity and tirzepatide’s role in body weight reduction.

Clinical recommendations for the management of type 1 diabetes (T1D) in older adults are urgently needed as the global population ages and as improved diabetes care and management of complications have extended the life expectancy of the patient population.

The therapy from AstraZeneca is indicated to improve glycemic control in patients aged 10 years or older.

In a session presented at the 2024 Heart in Diabetes Conference, researchers discussed the abilities of continuous glucose monitoring (CGM) to capture lifestyle data and improve mortality rates.

Four poster presented at ENDO 2024 examined the current landscape of diabetes.